Holen Sie sich die Stockscreener-App
1.55
0.00%
0.01
Handel nachbörslich:
1.55
Schlusskurs vom Vortag:
$1.54
Offen:
$1.51
24-Stunden-Volumen:
29,130
Relative Volume:
0.03
Marktkapitalisierung:
$4.72M
Einnahmen:
$129.20K
Nettoeinkommen (Verlust:
$-7.44M
KGV:
-0.1385
EPS:
-11.19
Netto-Cashflow:
$-8.62M
1W Leistung:
+6.94%
1M Leistung:
-10.98%
6M Leistung:
-73.54%
1J Leistung:
-89.19%
1-Tages-Spanne:
$1.48
$1.55
1-Wochen-Bereich:
$1.39
$1.57
52-Wochen-Spanne:
$1.38
$18.72
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
Firmenname
Sonnet Biotherapeutics Holdings Inc
Sektor
Branche
Telefon
609-375-2227
Adresse
100 OVERLOOK CENTER, PRINCETON, NJ
Vergleichen Sie SONN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SONN
Sonnet Biotherapeutics Holdings Inc
|
1.55 | 4.72M | 129.20K | -7.44M | -8.62M | -11.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Sonnet Biotherapeutics Holdings Inc Aktie (SONN) Neueste Nachrichten
Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update - ACCESS Newswire
Sonnet BioTherapeutics Highlights Promising SON-1010 Data - TipRanks
Sonnet BioTherapeutics Presents Innovative FHAB® Platform Data at 2025 AACR:IO Conference - Nasdaq
Sonnet BioTherapeutics Presents Compilation of Data - GlobeNewswire
Can This Immunotherapy Beat Solid Tumors? Sonnet's SON-1010 Shows 48% Clinical Benefit - StockTitan
Sonnet BioTherapeutics Announces Availability of Proprietary ADC Platform for Drug Discovery Partnerships - Defense World
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga
Sonnet BioTherapeutics advances novel ADC platform - Investing.com
SONN stock touches 52-week low at $1.38 amid market challenges - Investing.com India
Sonnet Biotherapeutics' Proprietary ADC Platform Available For Drug Discovery Partnerships - Marketscreener.com
Sonnet BioTherapeutics Announces That Its Proprietary - GlobeNewswire
Sonnet BioTherapeutics Advances Antibody Drug Conjugate Platform - TipRanks
Sonnet BioTherapeutics advances novel ADC platform By Investing.com - Investing.com South Africa
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street - The Globe and Mail
Can This New ADC Platform Challenge Established Cancer Drugs? Preclinical Data Shows Promise - StockTitan
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference - The Manila Times
Sonnet BioTherapeutics Announces Acceptance of Poster Presentation at 2025 AACR IO Conference - Nasdaq
Revolutionary Cancer Treatment Breakthrough: Sonnet's IL-12 Protein Research Heads to AACR 2025 - StockTitan
Sonnet BioTherapeutics appoints new chief business officer - MSN
Sonnet BioTherapeutics Issues Financial Results for Q4 2024, Reports Progress in Clinical Trials and Business Development - Defense World
Sonnet Biotherapeutics Reports Increased Revenue and Strategic Developments - TipRanks
Sonnet BioTherapeutics appoints new chief business officer By Investing.com - Investing.com Nigeria
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sonnet BioTherapeutics Holdings, Inc. SEC 10-Q Report - TradingView
Sonnet BioTherapeutics reports wider Q1 net loss, CFO transition - MSN
Sonnet Biotherapeutics Appoints Stephen Mcandrew As Chief Business Officer -February 13, 2025 at 08:40 am EST - Marketscreener.com
Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer - GlobeNewswire
Strategic Move: Biologics Deal-Making Veteran Takes CBO Role at Sonnet BioTherapeutics - StockTitan
Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update - GlobeNewswire
Sonnet BioTherapeutics (SONN) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Sonnet BioTherapeutics Announces Change in Date of Annual Meeting - ACCESS Newswire
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) Secures EU Patent for FHAB Platform Technology - Defense World
Sonnet BioTherapeutics secures EU patent for FHAB technology - Pharmaceutical Technology
Sonnet BioTherapeutics Secures EU Patent for FHAB Technology - TipRanks
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology - Marketscreener.com
Sonnet BioTherapeutics Further Expands Global Intellectual - GlobeNewswire
Game-Changing Cancer Drug Technology Gets Major EU Patent ProtectionHere's Why It Matters - StockTitan
Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum - ACCESS Newswire
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering - ACCESS Newswire
Sonnet BioTherapeutics to Present Clinical Data from the SB101 Study with SON-1010 at the AACR 2023 Annual Meeting - ACCESS Newswire
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy - ACCESS Newswire
Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement - ACCESS Newswire
Sonnet BioTherapeutics begins trial combining SON-1010, trabectedin - MSN
Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - GlobeNewswire
Sonnet BioTherapeutics to expand trial of SON-1010 with trabectedin for solid tumours - Clinical Trials Arena
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas - Defense World
Sonnet BioTherapeutics Expands Phase 1 Study for SON-1010 - TipRanks
Finanzdaten der Sonnet Biotherapeutics Holdings Inc-Aktie (SONN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.95%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):